Zhuk E A, Galenok V A
Ter Arkh. 1996;68(10):12-4.
Thymogen effect was assessed in patients with type 1 diabetes mellitus with clinical and laboratory evidence of secondary immunodeficiency. It was found that thymogen removes signs of secondary immunodeficiency due to activation of T-lymphocyte differentiation. Clinical effect of thymogen was registered in 94.4%, laboratory effect in 83.3% of patients. The scheme of thymogen administration is suggested.
在患有继发性免疫缺陷临床和实验室证据的1型糖尿病患者中评估了胸腺生成素的效果。发现胸腺生成素通过激活T淋巴细胞分化消除了继发性免疫缺陷的体征。94.4%的患者出现了胸腺生成素的临床效果，83.3%的患者出现了实验室效果。并提出了胸腺生成素的给药方案。
